Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Q2 Revenues Fall 60 Percent

NEW YORK (GenomeWeb) – Biocept today reported a 60 percent drop in its second quarter revenues.

In a Form 10-Q filed with the US Securities and Exchange Commission, the San Diego-based company said that for the three months ended June 30, revenues fell to $19,245 from $48,369 in the year-ago quarter. The decline, it said, resulted primarily from lower sample volume related to a collaboration with the Dana-Farber Cancer Institute that is approaching completion.

Biocept's net loss for the quarter was $3 million, or $.67 per share, compared to a net loss of $2 million, or $10.83 per share in Q2 2013. In the recently completed quarter, the firm used approximately 4.4 million shares to calculate its loss on a per-share basis, compared to 182,304 shares in the year-ago period. Biocept went public in February with an offering of 1.9 million shares.

The company said it had $12.5 million in cash and cash equivalents as of the end of Q2. In May Biocept entered into a $10 million loan and security agreement with Oxford Finance.

In afternoon trading on Monday, shares of Biocept were down about 4 percent on the Nasdaq at $4.70.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.